Accuray Incorporated — FY2023 Form 10-K
Reporting period: Fiscal year ended June 30, 2023. Although the request metadata says “2022 Q4,” this filing reports full-year FY2023 results, not standalone quarterly results. Amounts below are in U.S. dollars; financial statement figures are in millions unless stated otherwise.
Business context
Accuray develops, manufactures, sells and services radiation therapy systems, principally its CyberKnife and TomoTherapy/Radixact platforms, and related software. It reports one operating segment. International markets generated $325.3 million, or about 73% of revenue. China contributed $75.8 million (17%); the company also reported $32.6 million of Class A system revenue delivered in China during the year.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $447.6 | $429.9 |
| Product revenue | $233.2 | $214.7 |
| Service revenue | $214.4 | $215.2 |
| Gross profit / gross margin | $154.0 / 34.4% | $160.0 / 37.2% |
| Operating income | $2.4 | $8.1 |
| Net loss | $(9.3) | $(5.3) |
| Operating cash flow | $15.5 | $(2.4) |
| Cash and cash equivalents at year-end | $89.4 | $88.7 |
Revenue rose 4%, driven by product sales, while service revenue was nearly flat. Product gross profit declined 9%; management cited foreign exchange, inflation and unfavorable product mix. The overall gross margin fell 2.8 percentage points. Higher interest expense contributed to the larger net loss: other expense, net, was $11.7 million versus $10.4 million.
At June 30, 2023, current assets were $338.0 million and current liabilities were $198.6 million. Debt had $180.0 million principal outstanding ($177.3 million net carrying value): $100.0 million of 3.75% convertible notes due 2026, a $70.0 million term loan and $10.0 million drawn on the revolving facility. Operating cash flow improved primarily with collections, including an $18.5 million decrease in accounts receivable. Investing cash outflow was $12.7 million, including capitalized ERP-system costs.
Changes versus the prior year
- Gross orders decreased to $311.1 million from $332.3 million; net orders increased to $182.9 million from $167.3 million, partly because age-outs and cancellations declined.
- Year-end order backlog decreased to $510.6 million from $563.7 million. The annual book-to-bill ratio was 1.3, compared with 1.5.
- EIMEA revenue increased 16% to $155.9 million and Japan revenue increased 16% to $62.0 million; China revenue declined 13% to $75.8 million, which the company attributed in part to COVID-related restrictions.
- Accounts receivable, net, fell to $74.8 million from $94.4 million; inventory increased to $145.2 million from $142.3 million.
Outlook, risks and unusual items
- Management expects higher material, freight and logistics costs to continue pressuring gross margins and net income at least through FY2024, potentially longer. The filing gives no numerical revenue or earnings guidance.
- Management believes available cash, debt facilities and expected cash flows are sufficient for at least 12 months, but notes uncertainty around operating performance and compliance with debt covenants. Accuray was compliant at June 30, 2023; covenants become more stringent after that date. A default could accelerate debt, with substantially all assets pledged as collateral.
- The company recorded $2.7 million of cash-based restructuring charges after reducing its global workforce by 4.5%; no restructuring accrual remained at year-end. General and administrative expense included a $2.0 million bad-debt reserve related to a U.S. customer bankruptcy.
- Supply-chain constraints, inflation, foreign exchange, customer financing and installation delays, competition, reimbursement uncertainty, and reliance on single-source components are prominent risks. One customer represented at least 10% of revenue in FY2023, FY2022 and FY2021; the filing does not identify that customer in the supplied text.
- About 20% of open system-sales contracts, based on management’s estimate, may never produce revenue. Backlog can also be reduced by cancellations and age-outs and should not be treated as guaranteed sales.
- The company reported no current legal-proceeding losses that management considered both probable and reasonably estimable. It disclosed a voluntary Radixact recall initiated at the beginning of FY2024; the filing says earlier recall costs were not material and no serious adverse health consequences had been reported in connection with those recalls.
- The independent auditor issued an unqualified opinion on the financial statements and internal controls; management also concluded internal control over financial reporting was effective. The auditor identified allocation of transaction price to performance obligations using standalone selling prices as a critical audit matter.
Important facts for investors to verify
- Whether FY2024 margins and cash generation are affected as management expects by material, freight and logistics costs.
- Upcoming covenant calculations, available borrowing capacity and refinancing or repayment needs, particularly for the 2026 notes and credit facilities.
- Backlog quality and conversion: cancellations, age-outs, customer funding and installation readiness, including the estimate that roughly 20% of open system-sales contracts may not yield revenue.
- Exposure to the major customer, the customer bankruptcy and bad-debt reserve, and the scale and collectability of sales and receivables involving the China joint venture.
- Availability and cost of critical single-source components, inventory valuation, and the timing and impact of the FY2024 Radixact recall.